Skip to content

Effect Of Vibrapep Therapy On Breathing, Sputum Clearance, Oxygen Levels, And Breathlessness In Patients with Pneumonia

Effect of Vibrapep Therapy on Peak Expiratory Flow Rate, Sputum Volume, Oxygen Saturation, and Dyspnea Among Pneumonia Subjects: A Randomized Controlled Trial - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/02/103118
Enrollment
24
Registered
2026-02-05
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J189- Pneumonia, unspecified organism Health Condition 2: J189- Pneumonia, unspecified organism

Interventions

Intervention1: Group A Vibrapep: The patient is told to sit for extended periods of time in a relaxed position. The patient is told to take a deeper breath than usual starting at resting expiration. S

Sponsors

Prachi Pralhad Kambli
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects of all genders in the age group 41 to 65 years with pneumonia. 2. Community-Acquired Pneumonia within 48 hours of hospital admission or symptoms that appear outside of the hospital or within 48 hours of being admitted. 3. Hemodynamically stable subjects, such as controlled hypertension or diabetes, and with stable vitals. 4. Subjects who are willing to cooperate and follow commands.

Exclusion criteria

Exclusion criteria: 1. Ventilator-associated pneumonia or invasive mechanical pneumonia. 2. Hemodynamic instability such as pneumothorax, pulmonary embolism, etc. 3. Severe respiratory distress, SpO2 less than88% on oxygen therapy, systolic pressure less than 90 mmhg. 4. Recent thoracic surgery, 3-6 months post. 5. Neurological, cognitive, or musculoskeletal limitations. 6. Severe comorbid lung disease. 7. Uncooperative subjects.

Design outcomes

Primary

MeasureTime frame
Peak Expiratory Flow Rate Sputum VolumeTimepoint: Day 1 and Day 7

Secondary

MeasureTime frame
Oxygen Saturation [Pulse Oximeter] Dyspnea [Modified Borg Dyspnea Scale]Timepoint: Day 1 and Day 7

Countries

India

Contacts

Public ContactPrachi Pralhad Kambli

KAHER Institute of Physiotherapy

drganeshnssofficer@gmail.com9844857581

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026